ストックスクリーナーアプリを入手
1.72
15.65%
0.25
前日終値:
$1.47
開ける：
$1.82
24時間の取引高:
15.69M
Relative Volume:
9.39
時価総額：
$1.07M
収益：
$644.60K
当期純損益:
$-9.87M
株価収益率:
-0.00205
EPS:
-837.9618
ネットキャッシュフロー:
$-9.02M
1週間 パフォーマンス:
+38.22%
1か月 パフォーマンス:
-39.28%
6か月 パフォーマンス:
-69.37%
1年 パフォーマンス:
-94.14%
1日の値動き範囲:
$1.54
$1.91
1週間の範囲:
$1.14
$1.91
52週間の値動き範囲:
$1.14
$74.00
Biodexa Pharmaceuticals Plc Adr Stock (BDRX) Company Profile
BDRX を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
BDRX
Biodexa Pharmaceuticals Plc Adr
|
1.7146 | 1.07M | 644.60K | -9.87M | -9.02M | -837.96 |
|
VRTX
Vertex Pharmaceuticals Inc
|
477.83 | 125.40B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
577.18 | 65.79B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
555.52 | 35.18B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
237.96 | 32.67B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
239.91 | 26.46B | 3.81B | -644.79M | -669.77M | -6.24 |
Biodexa Pharmaceuticals Plc Adr Stock (BDRX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-02-08 | 開始されました | Ladenburg Thalmann | Buy |
Biodexa Pharmaceuticals Plc Adr (BDRX) 最新ニュース
Biodexa Pharmaceuticals advances FAP treatment trial By Investing.com - Investing.com South Africa
Biodexa Pharmaceuticals advances FAP treatment trial - Investing.com India
With Fast Track Designation in Hand, a Successful Protocol Discussion with FDA, and CROs in Place, Biodexa is on Track to Initiate its Funded Phase 3 Trial in FAP Next Quarter - Barchart.com
Biodexa gets FDA nod for Phase 3 eRapa study in FAP - Investing.com India
BDRXBiodexa Pharmaceuticals plc Latest Stock News & Market Updates - StockTitan
Biodexa selects Precision as CRO for eRapa Phase 3 study in Europe - Investing.com
Following Positive Phase 2 Results and Orphan Drug Designation, Biodexa's FAP Drug Receives FDA Fast Track Status - Barchart
Biodexa Pharmaceuticals Plc ADR [BDRX] Is Currently 31.94 above its 200 Period Moving Avg: What Does This Mean? - The DBT News
why Teva- Pharmaceutical Industries Ltd. ADR [TEVA] is a Good Choice for Investors After New Price Target of $24.71 - The DBT News
Palantir Technologies Inc [PLTR] Is Currently -0.39 below its 200 Period Moving Avg: What Does This Mean? - The DBT News
Biodexa Pharmaceuticals Plc ADR (BDRX) Stock: Navigating Market Highs and Lows in 52 Weeks - The InvestChronicle
Hesai Group ADR (HSAI) Shares Up Despite Recent Market Volatility - The News Heater
Biodexa Pharmaceuticals Plc ADR (BDRX) vs. Its Peers: A Comparison - The News Heater
Omega Therapeutics Inc (OMGA) Stock: A SWOT Analysis - The News Heater
AES Corp (AES) Shares Down Despite Recent Market Volatility - The News Heater
Altus Power Inc (AMPS) vs. Its Peers: A Comparison - The News Heater
Skechers (SKX) Earnings Expected to Grow: Should You Buy? - Yahoo Finance
Is Argenx (ARGX) Outperforming Other Medical Stocks This Year? - Yahoo Finance
Are Medical Stocks Lagging Argenx (ARGX) This Year? - Yahoo Finance
Biodexa Pharmaceuticals PLC Unsponsored ADR (BDRX) Moves to Buy: Rationale Behind the Upgrade - MSN
European Equities Traded in the US as American Depositary Receipts Start Week Higher in Monday Trading - MSN
Biodexa Pharmaceuticals Plc ADR (BDRX): A New Perspective - Stocks Register
Result of General Meeting - Yahoo Finance
Gaining Momentum, Biodexa Is Advancing Two Recent Acquisitions Through The Clinic - Barchart
Biodexa Pharmaceuticals regains Nasdaq compliance - Investing.com
Notice of General Meeting - StockTitan
Biodexa Pharmaceuticals Submits SEC Filing with Auditors’ Nod - TipRanks
BDRX INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Biodexa Pharmaceuticals Plc and Encourages Investors to Contact the Firm - GlobeNewswire Inc.
Biodexa reports promising glioblastoma trial results - Investing.com
Biodexa Pharmaceuticals releases patient updates on PFS, OS from MAGIC-1 study - TipRanks
Biodexa's MX-110 Continues to Show Promise in Recurrent Glioblastoma (rGBM), the Deadliest Brain Cancer - StockTitan
Stock Surge: Biodexa Pharmaceuticals Plc ADR (BDRX) Closes at 5.01, Marking a -4.21 Increase/Decrease - The Dwinnex
Biodexa Pharmaceuticals Secures Nasdaq Compliance Extension - TipRanks
Biodexa secures Nasdaq listing extension - Investing.com
Biodexa Pharmaceuticals granted extension to regain compliance with Nasdaq - TipRanks
Biodexa secures Nasdaq listing extension By Investing.com - Investing.com UK
Biodexa Announces Successful Appeal of Nasdaq Delisting - StockTitan
Biodexa provides update on PFS, OS in Phase 1 study of MTX110 in rGBM - TipRanks
Biodexa reports survival rates in glioblastoma study - Investing.com India
Biodexa reports updated Phase 1 data from glioblastoma study (NASDAQ:BDRX) - Seeking Alpha
Biodexa’s MTX110 Shows Promise in Brain Cancer Study - TipRanks
Biodexa reports survival rates in glioblastoma study By Investing.com - Investing.com UK
Biodexa Provides Update on Progression Free and Overall Survival in Phase 1 Study of MTX110 in Recurrent Glioblastoma - StockTitan
Should investors be concerned about BDRX’s high price-to-sales ratio? - US Post News
Interim results for the six months ended June 30, 2024 - StockTitan
Biodexa Pharmaceuticals Announces ADR Ratio Change - TipRanks
ADR Ratio Change - GlobeNewswire
Biodexa Pharmaceuticals announces ADR ratio change - Investing.com
Biodexa secures full access to cancer research grant - Investing.com
Biodexa Pharmaceuticals Plc ADR (BDRX) produces promising results - US Post News
Receipt of Nasdaq Delisting DeterminationPlans to Appeal - StockTitan
Biodexa Pharmaceuticals Plc Adr (BDRX) 財務データ
収益
当期純利益
現金流量
EPS
2.65%
0.06%
大文字化:
|
ボリューム (24 時間):